MCID: OBS005
MIFTS: 91

Obesity

Categories: Genetic diseases, Metabolic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Obesity

MalaCards integrated aliases for Obesity:

Name: Obesity 54 54 38 12 24 71 71 29 52 41 42 14 69
Obesity, Autosomal Dominant 54 29 13
Obesity, Severe, and Type Ii Diabetes 54 38
Obesity Due to Melanocortin 4 Receptor Deficiency 56
Body Mass Index Quantitative Trait Locus 10 29
Obesity, Mild, Early-Onset 54
Obesity, Association with 54
Obesity, Variation in 54
Obesity, Early-Onset 54
Obesity, Late-Onset 54
Obesity, Severe 54
Mc4r Deficiency 56

Characteristics:

Orphanet epidemiological data:

56
obesity due to melanocortin 4 receptor deficiency
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-5/10000 (France); Age of onset: Infancy,Neonatal;

OMIM:

54
Inheritance:
autosomal dominant
autosomal recessive
multifactorial

Miscellaneous:
variable phenotypic severity
see also leptin deficiency and summary information in bmiq1



Classifications:

Orphanet: 56  
Rare endocrine diseases


Summaries for Obesity

MedlinePlus : 41 obesity means having too much body fat. it is different from being overweight, which means weighing too much. the weight may come from muscle, bone, fat, and/or body water. both terms mean that a person's weight is greater than what's considered healthy for his or her height. obesity occurs over time when you eat more calories than you use. the balance between calories-in and calories-out differs for each person. factors that might affect your weight include your genetic makeup, overeating, eating high-fat foods, and not being physically active. being obese increases your risk of diabetes, heart disease, stroke, arthritis, and some cancers. if you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases. for example, that means losing 10 to 20 pounds if you weigh 200 pounds. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Obesity, also known as obesity, autosomal dominant, is related to obesity susceptibility, enpp1-related and obesity susceptibility, ghrl-related, and has symptoms including hypertriglyceridemia, hyperinsulinemia and hypertension. An important gene associated with Obesity is MC4R (Melanocortin 4 Receptor), and among its related pathways/superpathways are DAG and IP3 signaling and Circadian rythm related genes. The drugs Dexmedetomidine and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include liver, ovary and heart, and related phenotypes are adipose tissue and growth/size/body region

UniProtKB/Swiss-Prot : 71 Obesity: A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

Wikipedia : 72 Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have a... more...

Description from OMIM: 601665 607514

Related Diseases for Obesity

Diseases in the Obesity family:

Obesity, Mc4r-Related Obesity, Nr0b2-Related
Obesity, Pparg-Related Obesity, Ppargc1b-Related
Obesity, Pyy-Related Obesity, Sim1-Related
Obesity, Ucp3-Related

Diseases related to Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 748)
id Related Disease Score Top Affiliating Genes
1 obesity susceptibility, enpp1-related 31.4 ADRB2 DDHD2 GLDC GNAS MC4R POLG
2 obesity susceptibility, ghrl-related 31.4 ADRB3 DDHD2 GLDC GNAS MC4R POLG
3 obesity susceptibility, ucp1-related 31.4 DDHD2 ENPP1 GLDC GNAS MC4R POLG
4 obesity, ppargc1b-related 31.4 DDHD2 GLDC GNAS MC4R POLG UCP1
5 obesity, mc4r-related 31.3 DDHD2 GHRL GLDC GNAS MC4R POLG
6 thrombophilia 30.8 GHRL GNAS POMC
7 short bowel syndrome 30.6 ADRB3 ENPP1 GHRL
8 obesity, morbid, due to leptin receptor deficiency 12.1
9 obesity, adrenal insufficiency, and red hair due to pomc deficiency 12.1
10 mental retardation, truncal obesity, retinal dystrophy, and micropenis 12.1
11 obesity, morbid, due to leptin deficiency 12.0
12 morbid obesity and spermatogenic failure 12.0
13 retinal dystrophy and obesity 12.0
14 spastic paraplegia, intellectual disability, nystagmus, and obesity 12.0
15 abdominal obesity-metabolic syndrome 3 12.0
16 obesity with impaired prohormone processing 12.0
17 morbid obesity 12.0
18 obesity due to congenital leptin deficiency 12.0
19 obesity, hyperphagia, and developmental delay 11.9
20 aniridia - ptosis - intellectual disability - familial obesity 11.9
21 mental retardation, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and obesity 11.9
22 abdominal obesity-metabolic syndrome 1 11.9
23 hydrocephalus obesity hypogonadism 11.9
24 abdominal obesity-metabolic syndrome 11.8
25 intellectual disability, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and obesity 11.8
26 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 11.7
27 obesity due to sim1 deficiency 11.7
28 cohen syndrome 11.6
29 momo syndrome 11.6
30 obesity, severe bmiq9 11.6
31 obesity susceptibility, agrp-related 11.6
32 obesity bmiq12 11.6
33 x-linked intellectual disability - short stature - obesity 11.6
34 obesity susceptibility, pomc-related 11.6
35 obesity bmiq11 11.6
36 obesity, nr0b2-related 11.6
37 coloboma-obesity-hypogenitalism-mental retardation syndrome 11.6
38 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 11.6
39 monogenic non-syndromic obesity, autosomal recessive 11.6
40 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 11.6
41 obesity bmiq4 11.6
42 obesity susceptibility, adrb2-related 11.6
43 obesity susceptibility, adrb3-related 11.6
44 congenital leptin deficiency 11.6
45 x-linked intellectual disability-precocious puberty-obesity syndrome 11.6
46 obesity susceptibility, cartpt-related 11.6
47 obesity susceptibility, mc3r-related 11.6
48 x-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome 11.6
49 obesity bmiq14 11.6
50 obesity, pparg-related 11.6

Graphical network of the top 20 diseases related to Obesity:



Diseases related to Obesity

Symptoms & Phenotypes for Obesity

Symptoms via clinical synopsis from OMIM:

54

Metabolic Features:
obesity
reduced energy expenditure

Growth- Weight:
obesity


Clinical features from OMIM:

601665 607514

Human phenotypes related to Obesity:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertriglyceridemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002155
2 hyperinsulinemia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000842
3 hypertension 56 32 occasional (7.5%) Occasional (29-5%) HP:0000822
4 obesity 56 32 Obligate (100%) HP:0001513
5 acanthosis nigricans 56 32 occasional (7.5%) Occasional (29-5%) HP:0000956
6 polyphagia 56 32 hallmark (90%) Very frequent (99-80%) HP:0002591
7 type ii diabetes mellitus 56 32 occasional (7.5%) Occasional (29-5%) HP:0005978
8 increased adipose tissue 56 32 obligate (100%) Obligate (100%) HP:0009126
9 childhood-onset truncal obesity 56 32 frequent (33%) Frequent (79-30%) HP:0008915
10 decreased resting energy expenditure 32 HP:0012340

UMLS symptoms related to Obesity:


overweight, high weight, symptoms, obesity, metabolically benign, monogenic obesity

MGI Mouse Phenotypes related to Obesity:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.41 ADRB2 ADRB3 AGRP CARTPT ENPP1 FFAR4
2 growth/size/body region MP:0005378 10.32 PPARG PPARGC1B SDC3 SIM1 UCP1 UCP3
3 homeostasis/metabolism MP:0005376 10.32 DDHD2 ENPP1 FFAR4 GHRL GLDC GNAS
4 behavior/neurological MP:0005386 10.3 ADRB2 ADRB3 AGRP CARTPT DDHD2 ENPP1
5 endocrine/exocrine gland MP:0005379 10.14 POMC PPARG SIM1 ADRB2 ADRB3 CARTPT
6 cardiovascular system MP:0005385 10.09 ADRB2 ENPP1 GLDC GNAS MC4R POLG
7 nervous system MP:0003631 9.93 ADRB2 AGRP DDHD2 ENPP1 FFAR4 GLDC
8 liver/biliary system MP:0005370 9.91 AGRP ENPP1 FFAR4 GNAS MC4R NR0B2
9 no phenotypic analysis MP:0003012 9.56 POLG POMC PPARG PPARGC1B ADRB2 AGRP
10 skeleton MP:0005390 9.28 ADRB2 CARTPT ENPP1 GLDC GNAS MC4R

Drugs & Therapeutics for Obesity

Drugs for Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
2
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103-90-2 1983
3
Dalteparin Approved Phase 4,Phase 3,Phase 1 9005-49-6
4
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 9005-49-6 772 46507594
5
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2 138402-11-6 3749
6
Moxonidine Approved Phase 4 75438-57-2 4810
7
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
8
Orlistat Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 96829-58-2 3034010
9
Saxagliptin Approved Phase 4,Phase 2 361442-04-8 11243969
10
Levonorgestrel Approved, Investigational Phase 4,Phase 2 797-63-7, 17489-40-6 13109
11
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1 59467-70-8 4192
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 112809-51-5 3902
14
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
15
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
16
Mitiglinide Approved, Investigational Phase 4 145375-43-5 3047758
17
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 13422-51-0 11953898 5460373 44475014
18
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
19 Nadroparin Approved Phase 4 9041-08-1
20
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-23-7 5754 657311
21
Metyrapone Approved Phase 4 54-36-4 4174
22
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
23
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
24
Losartan Approved Phase 4,Phase 3,Phase 1,Phase 2 114798-26-4 3961
25
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
28
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
29
Rocuronium Approved Phase 4,Phase 2 119302-91-9, 143558-00-3 441290
30
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-93-5 3639
31
Clozapine Approved Phase 4,Phase 3,Phase 1 5786-21-0 2818
32
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
33
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
34
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
35
Ropivacaine Approved Phase 4,Phase 2,Early Phase 1 84057-95-4 71273 175805
36
Clonidine Approved Phase 4,Phase 2 4205-90-7 2803
37
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
38
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
39
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-78-2 2244
40
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
41
Enalaprilat Approved Phase 4 76420-72-9 6917719
42
Rimonabant Approved, Investigational Phase 4,Phase 3,Phase 2 168273-06-1, 158681-13-1 104850
43
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
44
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
45
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
46
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
47
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
48
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
49
Phentermine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 122-09-8 4771
50
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 8484)

id Name Status NCT ID Phase Drugs
1 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
2 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
3 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity Unknown status NCT01405352 Phase 4
6 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
7 The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
8 The Therapeutic Effect of Catgut Embedding in Obesity Unknown status NCT02276235 Phase 4
9 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
10 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
11 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
12 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
13 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
14 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
15 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
16 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
17 Levonorgestrel-releasing Intrauterine Device on Obese Women: Effects on Hemostatic and Arterial Function Unknown status NCT01320917 Phase 4
18 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
19 The Effects of Pentoxifylline on PAI-1 in an Obese Population Unknown status NCT00770328 Phase 4 Pentoxifylline;Placebo
20 Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
21 Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment Unknown status NCT01865448 Phase 4
22 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
23 Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children Unknown status NCT01878994 Phase 4
24 Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
25 Cardiovascular Effects of Metformin on Obesity Unknown status NCT01910246 Phase 4 Metformin
26 Children's Healthy Living Program Unknown status NCT01881373 Phase 4
27 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
28 Mechanisms Underlying Postoperative Insulin Resistance and Inflammation Unknown status NCT01470534 Phase 4
29 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
30 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
31 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
32 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
33 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
34 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
35 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
36 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
37 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4 Linezolid
38 Physical Activity and ARTs Unknown status NCT01892111 Phase 4
39 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
40 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
41 Effect of Daily Glucomannan in Overweight Patients Unknown status NCT01485718 Phase 4
42 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
43 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
44 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
45 Detemir Energy Expenditure Study Unknown status NCT00788840 Phase 4 Insulatard;Detemir
46 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
47 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
48 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
49 LAP-BAND Observational Cohort Unknown status NCT00283972 Phase 4
50 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide

Search NIH Clinical Center for Obesity

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: obesity

Genetic Tests for Obesity

Genetic tests related to Obesity:

id Genetic test Affiliating Genes
1 Obesity 29 24
2 Body Mass Index Quantitative Trait Locus 10 29
3 Obesity, Autosomal Dominant 29

Anatomical Context for Obesity

MalaCards organs/tissues related to Obesity:

39
Liver, Ovary, Heart, Breast, Brain, Testes, Kidney

Publications for Obesity

Articles related to Obesity:

(show top 50) (show all 10684)
id Title Authors Year
1
Removal notice to The relationship between primary cesarean delivery skin incision type and wound complicationsA inA women with morbid obesity: Am J Obstet Gynecol 2014;210:319.e1-4. ( 28648694 )
2017
2
A Review of the Impact of Maternal Obesity on the Cognitive Function and Mental Health of the Offspring. ( 28534818 )
2017
3
Long-Term Follow-Up of Autonomic and Enteric Measures in Patients Undergoing Vertical Banded Gastroplasty for Morbid Obesity. ( 28912907 )
2017
4
ZBTB16 gene variability influences obesity-related parameters and serum lipid levels in Czech adults. ( 28948827 )
2017
5
The cellular and molecular bases of leptin and ghrelin resistance in obesity. ( 28232667 )
2017
6
Maternal obesity is associated with chorioamnionitis and earlier indicated preterm delivery among expectantly managed women with preterm premature rupture of membranes. ( 28936902 )
2017
7
Ghrelin is independently associated with anti-mullerian hormone levels in obese but not non-obese women with polycystic ovary syndrome. ( 28004236 )
2017
8
Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. ( 28525998 )
2017
9
Obesity: Receptors identified for a weight regulator. ( 28953879 )
2017
10
Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. ( 28084147 )
2017
11
Influence of obesity on experimental periodontitis in rats: histopathological, histometric and immunohistochemical study. ( 28929308 )
2017
12
Regional Differences Between Perisynovial and Infrapatellar Adipose Tissue Depots and Their Response to Class II and Class III Obesity in Patients With Osteoarthritis. ( 28320058 )
2017
13
The impact of obesity on heart failure. ( 28092289 )
2017
14
OBESITY AND ATOPIC DERMATITIS, ALLERGIC RHINITIS. ( 28904285 )
2017
15
Intergenerational impact of maternal overnutrition and obesity throughout pregnancy in sheep on metabolic syndrome in grandsons and granddaughters. ( 28527530 )
2017
16
Royal jelly ameliorates diet-induced obesity and glucose intolerance by promoting brown adipose tissue thermogenesis in mice. ( 28089395 )
2017
17
Renal osteodystrophy in the obesity era: Is metabolic syndrome relevant? ( 28719612 )
2017
18
Associations of VCAM-1 gene polymorphisms with obesity and inflammation markers. ( 27853845 )
2017
19
A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorder. ( 28889945 )
2017
20
Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. ( 28288852 )
2017
21
The cytoskeletal protein septin 11 is associated with human obesity and is involved in adipocyte lipid storage and metabolism. ( 27866222 )
2017
22
The Clinical Characteristics of Obese Patients with Acanthosis Nigricans and Its Independent Risk Factors. ( 28081576 )
2017
23
Obesity-related genetic polymorphisms and adiposity indices in a young Italian population. ( 28090739 )
2017
24
Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. ( 28947312 )
2017
25
Effects of octreotide on hepatic glycogenesis in rats with high fat dieta89induced obesity. ( 28534956 )
2017
26
Decreased serum glicentin concentration in patients with severe and morbid obesity. ( 28661200 )
2017
27
Correlation of TLR4 and KLF7 in Inflammation Induced by Obesity. ( 27714571 )
2017
28
Pre- and postprandial acylated ghrelin in obese and normal weight men. ( 28625043 )
2017
29
Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. ( 28064111 )
2017
30
The Impact of Peroxisome Proliferator-Activated Receptor Gamma and Its Interaction with Abdominal Obesity on Diabetic Nephropathy in Chinese Han. ( 28013303 )
2017
31
Lower cellular metabolic power can be an explanation for obesity trend in Tae-Eum type: hypothesis and clinical observation. ( 28951839 )
2017
32
Fat intake and cardiac autonomic dysfunction in obese children: What is the relationship? ( 28673780 )
2017
33
Obesity and diabetes in 2017: a new year. ( 28091363 )
2017
34
A PDGFRI+-Mediated Switch toward CD9(high) Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis. ( 28215843 )
2017
35
Obesity and survival in critically ill patients with acute respiratory distress syndrome: a paradox within the paradox. ( 28532465 )
2017
36
Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". ( 28840448 )
2017
37
Rumination in Patients with Binge-Eating Disorder and Obesity: Associations with Eating-Disorder Psychopathology and Weight-bias Internalization. ( 28078784 )
2017
38
Plasma concentrations of caspofungin in a critically ill patient with morbid obesity. ( 28764793 )
2017
39
Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. ( 28821853 )
2017
40
Metabolically Activated Adipose Tissue Macrophages Perform Detrimental and Beneficial Functions during Diet-Induced Obesity. ( 28954231 )
2017
41
Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. ( 28636624 )
2017
42
Effect of Weight Loss after Bariatric Surgery on Thyroid-Stimulating Hormone Levels in Patients with Morbid Obesity and Normal Thyroid Function. ( 28725979 )
2017
43
The Relationship between Serum Zonulin Level and Clinical and Laboratory Parameters of Childhood Obesity. ( 28008865 )
2017
44
Serum and follicular fluid monocyte chemotactic protein-1 levels are elevated in obese women and are associated with poorer clinical pregnancy rate after inA vitro fertilization: aA pilot study. ( 28104240 )
2017
45
Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats. ( 27871838 )
2017
46
Temporal trends, center-level variation, and the impact of prevalent state obesity rates on acceptance of obese living kidney donors. ( 28949096 )
2017
47
Perilipin polymorphisms are risk factors for the development of obesity in adolescents? A case-control study. ( 28274232 )
2017
48
Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension. ( 27825280 )
2017
49
Validation of obesity susceptibility loci identified by genome-wide association studies in early childhood in South Brazilian children. ( 27005443 )
2017
50
Kidney disease and obesity: epidemiology, mechanisms and treatment. ( 28090083 )
2017